EnCureGen Pharma

EnCureGen Pharma is a South Korean biotechnology company specializing in the development of next-generation gene therapies using Adeno-associated virus (AAV) vectors. The company focuses on addressing unmet medical needs in ophthalmology and oncology through its proprietary AAV platform technology. Its lead candidates, EG-001 and EG-002, are designed to provide long-term therapeutic effects for retinal diseases such as wet age-related macular degeneration and diabetic retinopathy. EnCureGen aims to overcome the limitations of current treatments, such as the need for frequent intraocular injections, by delivering sustained gene expression. The company is actively engaged in capsid engineering to improve the safety and efficacy of its viral delivery systems.